Moolec Science SA filings document a foreign private issuer developing molecular farming and precision fermentation technologies for food-ingredient applications. Its Form 6-K reports and annual materials cover shareholder meeting matters, consolidated financial statements, board composition, Nasdaq continued-listing compliance, share consolidation, and incorporation of certain reports into its Form S-8 registration statement.
The filing record also documents capital-structure and control matters, including preference-share conversion and the emergence of a controlling shareholder, as well as accounting disclosures related to loss of control and derecognition of subsidiaries following bankruptcy proceedings. These disclosures frame the company’s governance, ownership, reporting status, and public-company obligations alongside its operating business.
Moolec Science reports a change in control after Agriculture Investment Group Corp. (AIGC) became its controlling shareholder. On April 1, 2026, AIGC held 65.1% of Moolec’s outstanding shares following a partial conversion of its preference shares into ordinary shares under an existing subscription agreement. As a foreign private issuer, Moolec has chosen to follow home country practice instead of Nasdaq’s usual requirement for prior shareholder approval in transactions that result in a change of control.
Moolec Science SA Chief Financial Officer Valeria Ines Falottico filed an initial insider ownership report listing her holdings in the company’s ordinary shares and equity awards. She directly holds 891 ordinary shares.
The filing also lists share options over 2,222 ordinary shares at an exercise price of $7.14 per share, with expiration dates in 2031, 2032, and 2033. In addition, she holds restricted share unit awards linked to 2,333 underlying ordinary shares at $14.28 per share and 2,333 underlying ordinary shares at $28.56 per share, both expiring in 2031.
Moolec Science SA director Lorenzo Varela has filed a Form 3 reporting his initial beneficial ownership in the company. The filing shows three direct option-based positions over ordinary shares, each with a $7.14 exercise price and expirations in 2031, 2032, and 2033.
The underlying options cover 934, 933, and 933 ordinary shares, respectively, and are structured as share options rather than open-market share purchases or sales. The disclosure is administrative, establishing his baseline holdings without reporting any new buy or sell transactions.
Moolec Science SA Chief Technology Officer Paola Alexandra Diaz Dellavalle filed an initial ownership report showing direct holdings of share options over ordinary shares. The filing lists options to acquire 934, 933 and 933 ordinary shares at an exercise price of $7.14 per share, with expiration dates in 2031, 2032 and 2033.
Moolec Science SA filed an initial insider holdings report for Chief Technology Officer Paola Alexandra Diaz Dellavalle. She holds share options over 934 ordinary shares at an exercise price of 7.1400 per share expiring on June 30, 2031, and additional options over 933 shares each expiring on June 30, 2032 and June 30, 2033. These entries reflect her option-based equity position rather than new share purchases or sales.
Moolec Science SA director Abelleyra Llodra Diego Juan has filed a Form 3 reporting direct holdings of share options over ordinary shares. The filing lists three option grants covering 934, 933 and 933 underlying ordinary shares at an exercise price of 7.1400, expiring on 2031-06-30, 2032-06-30 and 2033-06-30. These entries describe existing derivative positions rather than new open‑market purchases or sales.
Moolec Science SA filed an initial ownership report for Chief Executive Officer Alejandro Carlos Antalich, detailing his equity-based awards in ordinary shares. The filing lists share options for 3,334, 3,333 and 3,333 underlying shares at an exercise price of $7.1400, expiring between 2031 and 2033.
It also shows restricted share units linked to 6,667 and 6,666 underlying ordinary shares at exercise prices of $14.2800 and $28.5600, expiring on February 6, 2031. These entries describe existing awards and do not reflect new open-market purchases or sales.
Moolec Science SA director Leon Bentancor Oscar Alejandro filed an initial Form 3 reporting option-based holdings in the company’s ordinary shares. He holds three direct share option positions, each with an exercise price of 7.1400 per share, covering 934, 933 and 933 ordinary shares with expirations in 2031, 2032 and 2033.
Moolec Science SA reported the initial holdings of its General Counsel, Gloria Montaron Estrada, in a Form 3. She directly holds 1,909 ordinary shares of the company as of the reported date, and the filing does not record any new share purchases or sales.
Moolec Science SA reported changes to its Board of Directors. Daniel Core has been appointed to the Board, effective February 25, 2025, and will also serve on the Audit Committee and the Compensation Committee. On the same date, directors Aimar Dimo and Gloria Montaron Estrada resigned from the Board. The company thanked both departing directors for their service. Moolec Science focuses on engineering plants and microbes to produce scalable protein ingredients for the global food system and is listed on Nasdaq under the ticker MLEC.